Dual blockade strategies such as cabozantinib (anti-c-MET) plus durvalumab (anti-PD-L1) have shown activity in MSS CRC by concurrently suppressing angiogenesis and reprogramming the tumor immune microenvironment. The gene discussed is CD274; the disease is neoplasm.